Traditional CAR-T cell therapy for hepatocellular carcinoma cause serious side effects, including cytokine release syndrome (CRS), and the AFP peptide-MHC complex is less expressed on the surface of tumor cells. This evidence concerns the gene HLA-C and hepatocellular carcinoma.